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AbstrAct
A disintegrin And metAlloproteAse 17 (AdAm17) appears to be recognized as an impor-
tant player in tissue destruction and also exacerbation of inflammation related with increased activities 
of angiogenesis in several pathological conditions. To examine the modulation of serum levels of ADAM17 
and inflammatory cytokines in patients with rheumatoid arthritis (RA) in response to therapy of abatacept 
(ABT). Twenty four patients with RA were enrolled in our study. Serum was collected immediately prior to 
(baseline) and 24 weeks after starting ABT therapy. Serum levels of ADAM17 and cytokines/chemokine were 
quantified using enzyme-linked immunosorbent assay. ADAM17 level was markedly higher in RA patients 
than in healthy individuals. Positive correlation was observed between the baseline ADAM17 and CX3CL1 
at baseline. There was a significant overall reduction of RA disease activity (Disease Activity Score 28) from 
4.73 to 2.79 after 24 weeks after the ABT therapy. Furthermore, there was a significant reduction in serum 
level of ADAM17 in RA patients, and the patients achieved clinical responses, and also clinical remission had 
a significant decrease in ADAM17 level and also levels of tumor necrosis factor α, IL-6 and CX3CL1 after 24 
weeks of ABT therapy. Our results suggest that the suppression of ADAM17 secretion and function seems to 
be a crucial therapeutic target in the treatment of ABT in patients with RA.
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introduction
The complicated networks between inflammatory/im-
mune cells and pro-inflammatory molecules with poten-
tially important roles have been implicated in the patho-
genesis of rheumatoid arthritis (RA) (1-3). Numerous 
mediators, including inflammatory cytokines and adhe-
sion molecules, have been implicated in this process (2, 
4). In a recent decade, the crucial therapeutic targets to 
ORIGINAL ARTICLE
ADAM17 in RA tReAteD with AbAtAcept
101
inhibit the disease activities of RA were focused to these 
cytokines such as tumor necrosis factor (TNF) and IL-6 
(5-7). In addition, it has been more recently demonstrated 
that the inhibition of T lymphocyte activation was recog-
nized as an effective to suppress RA activities. Abatacept 
(ABT) is a fusion protein that consists of the extracellular 
domain of human cytotoxic T-lymphocyte-associated anti-
gen 4 (CTLA-4) linked to a modified Fc portion of human 
immunoglobulin G1 (IgG1), and selectively modulates the 
CD80/CD86:CD28 costimulatory signal, resulting the in-
hibition of activation and proliferation of T lymphocytes 
(8). ABT has introduced clinical improvement in signs 
and symptoms, disability, and significantly inhibited the 
progression of joint damage in early and long-standing 
disease (9).
A disintegrin and metalloprotease 17 (ADAM17) or 
tumor necrosis factor-α converting enzyme (TACE) was 
first described as the protease responsible for TNFα shed-
ding (10, 11), and this enzyme was involved in the physio-
logical cleavage of membrane-anchored cytokines, includ-
ing TNFα and fractalkine (CX3CL1) (10-12), releasing it 
in soluble form. ADAM17 was also shown to solubilize a 
wide variety of proteins including TNF receptors (R) (13), 
and IL-6R (14). In addition, the implication of ADAM17 
substrates in immunoregulation has made this enzyme an 
efficient therapeutic target in the treatment of a number 
of pathological conditions including airway inflamma-
tion, cancer, and arthritis (15, 16). Also, an elevated level 
of ADAM17 expression was found in synovial tissue and 
mainly in macrophage- and fibroblast-like synovial cells 
and also cartilage in patients with RA, as compared with 
patients with osteoarthritis, and with normal cartilage 
(17-19), suggesting that abnormal ADAM17 activity and 
expression may contribute to the development of several 
pathological conditions, including RA.
The aim of the present study was to examine the modu-
lation of ADAM17 and also inflammatory cytokines/che-
mokines including TNFα and CX3CL1 in patients with 
RA in response to therapy of ABT, since ADAM17 is the 
predominant protease catalyzing the release of crucial cy-
tokines that are involved in a cascade of events leading to 
RA.
mAteriAls And methods
patients
The study design was a prospective observational co-
hort study. Twenty four patients with RA and who fulfilled 
the 1987 American College of Rheumotology (ACR) crite-
ria (20) were enrolled in our study between 2011 and 2013. 
All patients failed to respond to treatment with methotrex-
ate (MTX) or other either biologic- or non-biologic disease 
modifying anti-rheumatic drugs (DMARDs), and patients 
who were needed to consider the changes of treatments 
by judged by the treating physician were also enrolled. 
Glucocorticoids (<10 mg/day of prednisolone) and non-
steroidal anti-inflammatory drugs had to have been given 
at a stable dose for at least 4 weeks (wks) prior to enroll-
ment and during the course of treatment in the study. Pa-
tients received intravenous ABT at a dose of 500 mg or 
750 mg (≤60 kg or >60 kg of body weight, respectively) at 
baseline and after 2, 4 and every 4 weeks. Disease activ-
ity and its clinical improvement were assessed using Dis-
ease Activity Score (DAS28) [erythrocyte sedimentation 
rate (ESR) 4] with European League Against Rheumatism 
(EULAR) response criteria (21). Remission was defined as 
DAS28-ESR < 2.6 after 24 wks of treatment. Functional 
ability was assessed with the modified Health Assessment 
Questionnaire (mHAQ) score. In the period of study (24 
wks from therapy), there was no alteration of their doses 
of medications including MTX, other DMARDs and pred-
nisolone.
serum samples
Serum was collected immediately prior to (baseline) 
and 24 wks after starting ABT therapy. In addition, con-
trol serum was obtained from twenty four age- and sex-
matched healthy volunteers (n=24). Serum rheumatoid 
factor (RF), matrix metalloproteinase (MMP-3), C-reac-
tive protein (CRP) levels, and ESR were determined us-
ing a latex photometric immunoassay and the Westergren 
method, respectively. Anti-cyclic citrullinated protein an-
tibody (ACPA) was measured using commercial double 
ligand enzyme-linked immunosorbent assays (ELISA) kit 
(Diastat Anti-CCP; MBL Tokyo, Japan).
All experiments were carried out in accordance with 
protocols approved by the Human Subjects Research Com-
mittee at our institution, and all human experiments were 
performed in accordance with the Declaration of Helsinki, 
and informed consent was obtained from all patients and 
volunteers.
Determination of serum levels of ADAM17 and cytokines
Serum levels of ADAM17 and the cytokines, including 
TNFα, IL-6, CX3CL1 (fractalkine), CXCL8 (IL-8), CCL2 
(monocyte chemoattractant protein-1), CCL3 (macrophage 
inflammatory protein-1 alpha) were quantified using com-
mercial ELISA kits according to the manufactures’ in-
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structions (R＆D Systems, Minneapolis, MN, USA ).
Because it is possible that the anti-IgG activity of the 
RF in the samples may have augmented the reactivity of 
the ELISA systems for cytokines and ADAM17, we also 
assayed ADAM17 and cytokines in five randomly cho-
sen serum samples before and after depleting RF using 
RF Stripper (Binding Site, Birmingham, UK). No sig-
nificant differences in serum levels of all cytokines were 
found between the RF-depleted and untreated sera (data 
not shown).
statistical analysis
Data were expressed as means ± standard deviation 
of the mean. The differences between groups were evalu-
ated using the Mann-Whitney U-test. Follow-up data were 
evaluated using Wilcoxons signed rank test. The relation-
ship between serum cytokine levels and the RA disease 
activity and indicated measures was evaluated using the 
Speaman rank correlation. Values of p<0.05 were consid-
ered significant.
results
Serum ADAM17 levels in RA patients
The patient characteristics are summarized in Table 1. 
Twenty-four RA patients with ABT therapy were enrolled 
in the present study. At the start of therapy, the mean age 
of the patients was 64.7 years, disease duration was 10.4 
years, and the baseline DAS28 was 4.73. We initially used 
ELISA to compare the ADAM17 levels in serum samples 
from all RA patients and from healthy individuals (n=24). 
ADAM17 levels were markedly higher in RA patients than 
in healthy controls (Fig. 1; p<0.0001). At baseline, there 
was no significant correlation between the serum levels of 
table 1. Patient characteristics and clinical responses by group
All Responsive group
Unresponsive 
group p remission non-remission p
Patients (male/female) 24 (5/19) 21 3 10 14
Age (yrs) 64.7 ± 10.9 65.9 ± 9.0 56.0 ± 20.3 n.s. 61.0 ± 13.2 67.3 ± 8.3 n.s.
Disease duration (yrs) 10.4 ± 1.9 6.4 ± 5.0 11.6 ± 17.6 n.s. 6.0 ± 5.1 7.8 ± 8.5 n.s.
Dosage of MTX (mg/wk) 8.3 ± 5.0 8.3 ± 4.9 8.0 ± 6.9 n.s. 10.1 ± 4.1 7.0 ± 5.4 n.s.
% positive 83.3 85.7 66.7 n.s. 100.0 71.4 n.s.
Prednisolone (mg/day) 2.9 ± 2.7 3.0 ± 2.7 2.0 ± 2.6 n.s. 2.6 ± 2.0 3.0 ± 3.2 n.s.
% positive 66.7 71.4 66.7 n.s. 70.0 64.3 n.s.
ESR (mm/h) 30.3 ± 19.3 31.2 ± 19.7 24.0 ± 19.1 n.s. 24.3 ± 18.2 34.6 ± 19.6 n.s.
CRP (mg/dl) 1.7 ± 2.2 1.7 ± 2.2 1.4 ± 2.2 n.s. 1.8 ± 2.7 1.5 ± 1.8 n.s.
TJC 10.9 ± 1.8 8.0 ± 4.6 3.3 ± 4.0 n.s. 4.9 ± 3.5 9.1 ± 4.8 n.s.
SJC 6.2 ± 0.8 5.3 ± 4.0 3.0 ± 4.4 n.s. 4.1 ± 5.0 5.7 ± 3.2 n.s.
DAS28 (ESR-4) 4.7 ± 1.5 5.0 ± 1.3 3.1 ± 2.1 n.s. 3.8 ± 1.7 5.4 ± 0.8 n.s.
mHAQ 1.5 ± 1.5 1.7 ± 1.6 1.0 ± 1.7 n.s. 0.2 ± 0.3 2.5 ± 1.3 <0.0001
RF (IU/ml) 114.9 ± 168.8 104.6 ± 157.4 186.6 ± 266.6 n.s. 122.4 ± 223.8 109.5 ± 125.3 n.s.
% positive 87.5 90.5 66.7 n.s. 70.0 100.0 n.s.
MMP-3 (ng/ml) 244.7 ± 212.4 263.9 ± 219.2 110.3 ± 85.4 n.s. 205.7 ± 260.2 272.5 ± 175.9 n.s.
ACPA (U/ml) 343.9 ± 472.6 387.5 ± 490.5 38.5 ± 50.3 n.s. 45.2 ± 63.5 557.3 ± 524.2 <0.005
% positive 79.2 76.2 66.7 n.s. 60.0 85.7 n.s.
Biologics-naïve pts (n) 8 8 0 4 4
ACPA, anti-cyclic citrullinated protein antibody; CRP, C-reactive protein; DAS28, disease activity score 28; ESR, erythrocyte sedimenta-
tion rate; mHAQ, modified health assessment questionnaire; MMP-3, matrix metalloproteinase-3; MTX, methotrexate; n.s., not signifi-
cant; pts, patients; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; wk, week; yrs, years.
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ADAM17 and either RA disease activity or serum mea-
sures including RF, ACPA, and MMP-3 (data not shown). 
Because it is known that ADAM17 is involved in the 
physiological cleavage of membrane-anchored inflamma-
tory cytokines, serum cytokine levels were examined in 
patients with RA at baseline. Positive correlation was ob-
served between the baseline ADAM17 and CX3CL1 (CX-
3CL1: Spearman’s rank correlation coefficient [rs] = 0.59, 
p<0.005, Fig. 2). In addition, the weak correlation was 
observed between ADAM17 and TNFα (rs=0.41, p=0.05), 
although there was no significant correlation between the 
baseline ADAM17 and IL-6.
reduction of ADAM17 levels with response to ABT 
therapy in patients with RA
In RA patients, there was a significant overall reduc-
tion of RA disease activity (DAS28) from 4.73 ± 1.48 to 
2.79 ± 1.07 (p<0.0001) after 24 wks after the ABT therapy. 
In addition, 21 patients treated with ABT achieved moder-
ate and good responses, and remission (DAS28-ESR<2.6) 
was induced in 10 patients. However, there were no signifi-
cant differences in patient characteristics and laboratory 
parameters at baseline between the remission group and 
nonremission group, except for mHAQ sores and ACPA 
titers, while no significant differences were seen in all pa-
rameters between the responsive and unresponsive groups 
(Table 1).
We next examined the changes of ADAM17 levels in 
patients with ABT therapy. After ABT therapy, there was a 
significant reduction (p<0.05) in serum levels of ADAM17 
in RA patients, although ADAM17 level in 5 patients was 
below a detection level (<10 pg/ml as zero value) of ELISA 
at both baseline and after medication (Fig. 3). We next 
analyzed the relation between changes in serum ADAM17 
levels and clinical responses to ABT therapy. There was a 
significant reduction in serum ADAM17 levels in the re-
sponsive group (n=21, 1182.7 ± 1858.9 (baseline) to 543.8 
± 710.0 pg/ml, p<0.05), but not in the unresponsive group 
Figure 1. Serum ADAM17 level in patients with RA and 
healthy individuals. Serum was obtained from patients at base-
line and healthy individuals. Serum ADAM17 was assayed by 
ELISA. *p<0.0001 vs healthy individuals (controls).
Figure 2. Positive correlation between serum levels of ADAM17 
and CX3CL1. Serum was obtained from patients at baseline. 
Serum ADAM17 was assayed by ELISA. Each point represents 
a sample collected from a different RA patient. Positive correla-
tion was observed between the baseline ADAM17 and CX3CL1 
(Spearman’s rank correlation coefficient [rs] = 0.59, p<0.005).
Figure 3. Effect of ABT therapy on ADAM17 level in RA 
patients Serum was obtained from patients at baseline and after 
24 weeks of ABT therapy. A significant reduction in serum 
ADAM17 level was observed after ABT treatment (*p<0.05).
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(Fig. 4A). Furthermore, serum ADAM17 levels were sig-
nificantly decreased in the group (n=10, 1257.1 ± 2254.6 vs. 
509.1 ± 892.5 pg/ml, p<0.05) achieved clinical remission 
after 24 wks of ABT therapy (similarly ADAM17 level in 
5 patients was below a detection level at both baseline and 
after medication) (Fig. 4B), although there were no statisti-
cally significances for baseline ADAM17 levels between 
any response groups (data not shown). Because patient 
groups are heterogeneous such as the primary and second-
ary non-responder groups to prior biologics (TNF or IL-6 
antagonists) and biologics-naïve groups, we examined the 
alteration of DAM17 in only biologic-naïve patients (n=8). 
ADAM17 was decreased from 1352.6 ± 1756.8 pg/ml to 
442.1 ± 551.4 pg/ml (p<0.05) in biologic-naïve patients 
after ABT therapy, although there was no significant re-
duction of ADAM17 in the unresponsive group with prior 
biologics.
At last, changes of serum cytokine levels were examined 
after 24 wks of ABT therapy. As well as ADAM17, serum 
concentrations of TNFα, IL-6 and CX3CL1 were signifi-
cantly decreased in all RA patients and also patients with 
clinical responses after 24 wks of ABT therapy, as shown in 
Table 2. While, there were no significant changes of serum 
concentrations of other chemokines, including CXCL8, 
CCL2, and CCL3 after ABT therapy in either all RA pa-
tients or those with any clinical responses (data not shown).
Figure 4. The relation between changes in serum ADAM17 level and clinical responses to ABT therapy. Panel A: A significant reduc-
tion in serum ADAM17 level was observed in the responsive group (n=21, *p<0.05), but not in the unresponsive group. Panel B: Serum 
ADAM17 levels were significantly decreased in the group achieved clinical remission (n=10, *p<0.05) after 24 weeks of ABT therapy.
Table 2. Changes in serum concentrations of ADAM17 and cytokines in RA patients taking ABT therapy
All rA patients (n=24) Responsive group (n=21) Unresponsive group (n=3)
baseline 24 wks p baseline 24 wks p baseline 24 wks p
TNFα (pg/ml) 87.9 ± 203.5 17.1 ± 25.4 <0.01 99.6 ± 215.6 18.6 ± 26.9 <0.005 6.2 ± 5.7 7.0 ± 6.1 n.s
IL-6 (pg/ml) 23.5 ± 37.5 8.7 ± 22.8 <0.05 26.4 ± 39.3 9.5 ± 24.3 <0.01 3.4 ± 2.0 3.5 ± 4.9 n.s
CX3CL1 (pg/ml) 2648.6 ± 
2518.9
1986.0 ± 
2868.8
<0.05 2836.1 ± 
2569.5
2053.4 ± 
3032.0
<0.05 1336.5 ± 
1996.8
1514.4 ± 
1526.7
n.s
ABT, abatacept; ADAM17, a disintegrin and metalloprotease domain 17; CX3CL1, chemokine (C-X3-C motif) ligand 1; IL-6, interleu-
kin-6; TNFα, tumor necrosis factor α; n.s., not significant.
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discussion
It has been known that enzymes such as ADAM as 
well as MMP, play a crucial role in the destruction of 
joint structures including bone and cartilage in RA sy-
novitis (22). ADAM10 is one of an important enzyme, 
and is observed in synovial tissues and fluids in patients 
with RA (23, 24). Recently, ADAM17 appears to be rec-
ognized as another important player in tissue destruction 
and also exacerbation of inflammation related with in-
creased activities of angiogenesis, as well as ADAM10. 
ADAM17 constitutively expressed by several cell types, 
including T cells, monocytes, endothelial cells, and fi-
broblasts (10), and increased expression of ADAM17 was 
observed in synovial tissue, as compared with patients 
with osteoarthritis, and was mainly seen in macrophage- 
and fibroblast-like synovial cells (18, 19). Furthermore, 
it has been demonstrated that ADAM17 is induced upon 
exposure to hypoxia and TNFα, which are important fac-
tors in rheumatoid synovitis (17, 19). In the present study, 
we showed that serum concentration of ADAM17 was in-
creased in patients with RA in compared to normal indi-
viduals, and a significant correlation between ADAM17 
and CX3CL1, which is involved in the pathogenesis of 
rheumatoid synovitis and also related vasculitis (25-27), 
was seen in RA patients at baseline. It is well known that 
ADAM17 is a crucial protease responsible for the con-
version of TNFα and CX3CL1 from a membrane-bound 
precursor to a soluble cytokine (10-12, 28). In the pres-
ent study, it has been shown that there was a significant 
reduction in serum ADAM17 levels in the responsive 
group, but not in the unresponsive group, and also in pa-
tients with a clinical remission after ABT therapy. In ad-
dition with ADAM17, similar decreases of serum levels 
of TNFα, IL-6 and CX3CL1 were observed after ABT 
therapy in RA patients (Table 2). ABT induces the de-
crease in peripheral blood of cytokine (IL-17 and IFN-γ)-
producing T cells and in serum IFN-γ in response with 
improved disease activity (29-31). In this regard, Marti et 
al. have reported that no significant reduction of serum 
TNFα, levels was seen in patients after ABT (CTLA4Ig) 
therapy (30), in contrast with our results. These conflict 
data in cytokine modulation in serum may be due to dif-
ferences in the short observational periods (12 wks) and 
small sample numbers (n=7) in the report by Marti, et al. 
Collectively, ADAM17 would be an important to modu-
late cytokine expression and to cleavage from cells, and 
also seems to be sensitive for effectiveness of ABT ther-
apy in patients with RA.
On the other hand, ADAM17 mRNA has been shown 
to be highly expressed in the thymus and spleen, and high 
ADAM17 protein levels have been detected in T cells, as 
described above, suggesting that ADAM17 may play an 
important role in T cell development and/or function (10, 
32). Indeed, ADAM17 expression was augmented by T 
cells in response to bacterial (Porphyromonas gingivalis) 
stimulation (33), indicating that T cell activation is crucial 
factor for stimulated expression of ADAM17. Recently, 
it has been demonstrated that circulating CD4+CD28- T 
cells decrease in parallel with decreased RA activity in re-
sponse with ABT (31, 34, 35). In the present study, serum 
concentration of ADAM17 was reduced after ABT therapy 
in RA patients, suggesting that deactivation and decreased 
numbers of T lymphocytes induced by ABT may be in 
part responsible for the reduction of ADAM17 levels.
Taken together, the orchestration and modulation of 
inflammatory cytokines via ADAM17 may account for 
the augmentation of abnormal inflammatory/immune re-
sponses in the pathogenesis of RA synovitis. Moreover, 
ABT may be induced to improve synovial inflammation 
through terminating inflammatory cytokine networks 
by, in part, inhibiting ADAM17 and consequently dis-
ease activity in RA patients as well as the inhibition of 
T lymphocyte activation, although direct mechanisms 
or interaction of inflammatory mediators such as TNFα, 
IL-6 and CX3CL1 by ABT therapy have not been still 
resolved in the present study. Since the limitations of the 
present study are that the number of enrolled patients is 
relatively small, future studies should be performed in 
the large number of RA patients to confirm the patho-
physiological role of ADAM17 in the course of RA with 
biologics such as ABT or antagonists for TNF or IL-6. 
Finally, the inhibition of ADAM17 expression and secre-
tion seems to be a crucial therapeutic target in the treat-
ment of ABT in patients with RA.
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